ibandronic acid has been researched along with Kahler Disease in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Alegre, A; Bailén, A; Giraldo, P; Gironella, M | 1 |
| Ehrenfeld, M; Mayr, D; Oduncu, F; Otto, S; Pautke, C; Troeltzsch, M | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Geng, CJ; Liang, Q; Liang, R; Meng, FY; Wu, N; Yuan, BY; Zhong, JH; Zhu, M | 1 |
| Bergner, R; Henrich, DM; Hoffmann, M; Uppenkamp, M | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Fernández, M; Figueroa, P; Pino, AM; Rodríguez, JP | 1 |
| Cevreska, L; Jovanovic, R; Karanfilski, O; Pavkovic, M; Petrushevska, G; Stankovic, S; Stojanovic, A | 1 |
| de la Fuente, J; Goldman, JM; Karkantaris, C; Meletis, J; Palermos, J; Rahemtulla, A; Terpos, E; Vaiopoulos, G; Viniou, N; Voskaridou, E; Yataganas, X | 1 |
| Body, JJ | 1 |
| Bian, SG; Jiang, ZF; Li, LQ; Song, ST; Wang, T; Wang, YJ; Zhu, J | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Jackson, GH | 1 |
| Bell, R | 1 |
| Bergner, R; Henrich, D; Hoffmann, M; Uppenkamp, M | 1 |
| Bergner, R; Henrich, DM; Hoffmann, M; Honecker, A; Mikus, G; Nagel, D; Nauth, B; Uppenkamp, M | 1 |
| McKeage, K; Plosker, GL | 1 |
| Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD | 1 |
| Bauss, F; Boyce, BF; Dallas, MR; Dallas, SL; Garrett, IR; Mundy, GR; Oyajobi, BO; Radl, J | 1 |
| Black, C; Coleman, RE; Huss, H; Kanis, J; Purohit, OP; Quinn, KJ; Schlosser, K; Vinholes, JJ | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M | 1 |
| Asosingh, K; Croucher, PI; Hughes, DE; Lippitt, JM; Rogers, MJ; Russell, RG; Shipman, CM; Van Camp, B; Vanderkerken, K | 1 |
| Alsina, M; Anderson, JL; Craig, F; Cruz, JC; Dallas, M; Roodman, GD; Yoneda, T | 1 |
| Boewer, C; Delmas, PD; Euller-Ziegler, L; Facon, T; Fiere, D; Fontana, A; Herrmann, Z; Hrubisko, M; Lichinitser, MR; Menssen, HD; Sakalová, A; Singer, CR; Thiel, E; Wetterwald, M | 1 |
9 review(s) available for ibandronic acid and Kahler Disease
| Article | Year |
|---|---|
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Root resorption caused by jaw infiltration of multiple myeloma: report of a case and literature review.
Topics: Aged; Antineoplastic Agents; Bicuspid; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Humans; Ibandronic Acid; Male; Mandibular Neoplasms; Molar; Multiple Myeloma; Neoplasm Invasiveness; Osteolysis; Root Resorption; Stem Cell Transplantation; Tooth Mobility | 2014 |
Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Europe; Humans; Ibandronic Acid; Multiple Myeloma; Musculoskeletal Pain; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Renal safety of ibandronate.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Kidney; Multiple Myeloma; Renal Insufficiency; Urologic Neoplasms | 2005 |
Efficacy of ibandronate in metastatic bone disease: review of clinical data.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Colorectal Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Multiple Myeloma; Treatment Outcome | 2005 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate | 1998 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
6 trial(s) available for ibandronic acid and Kahler Disease
| Article | Year |
|---|---|
Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2009 |
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Topics: Acid Phosphatase; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Bone Resorption; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Interleukin-6; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pamidronate; Peptides; Tartrate-Resistant Acid Phosphatase | 2003 |
[Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Phosphorus; Pruritus | 2004 |
Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency | 2007 |
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Biomarkers; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
Topics: Bone Resorption; Chi-Square Distribution; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain; Spinal Cord Compression; Survival Analysis; Treatment Outcome | 2002 |
11 other study(ies) available for ibandronic acid and Kahler Disease
| Article | Year |
|---|---|
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow Cells; Cells, Cultured; Diphosphonates; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Ibandronic Acid; Interleukin-1beta; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; RANK Ligand; Signal Transduction; Stromal Cells | 2010 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Pamidronate | 2010 |
Is ibandronate effective in multiple myeloma?
Topics: Bone Resorption; Diphosphonates; Humans; Ibandronic Acid; Multiple Myeloma; Randomized Controlled Trials as Topic | 2003 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports.
Topics: Acute Kidney Injury; Aged; Calcium; Creatinine; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Nephrocalcinosis | 2006 |
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Ibandronic Acid; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasms, Experimental | 1999 |
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Topics: Alendronate; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Bone Marrow Cells; Cell Division; Cell Survival; Cytotoxicity, Immunologic; Diphosphonates; Humans; Ibandronic Acid; Interferon-gamma; Interleukin-2; Kinetics; Lectins, C-Type; Lymphocyte Activation; Multiple Myeloma; Pamidronate; Plasma Cells; Receptors, Interleukin-2; T-Lymphocytes; Tumor Cells, Cultured | 2000 |
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Topics: Animals; Apoptosis; Bone Marrow Cells; Diphosphonates; Ibandronic Acid; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasms, Experimental; Treatment Failure; Tumor Cells, Cultured | 2000 |
Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
Topics: Animals; Bone Diseases; Bone Marrow Cells; Cell Division; Cell Survival; Diphosphonates; Disease Models, Animal; Humans; Hypercalcemia; Ibandronic Acid; Immunoglobulin G; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Osteolysis; Paraplegia; Tumor Cells, Cultured | 2001 |